<DOC>
	<DOCNO>NCT01265537</DOCNO>
	<brief_summary>While incidence acute rejection early graft loss improve dramatically advent newer immunosuppressant medication , improvement long-term patient allograft survival kidney transplantation achieve . The specific drug combination provide best outcomes least amount side effect know . Each kidney transplant center use combination drug believe optimal . This study identify whether drug currently approve use kidney transplantation use new combination safely potentially few side effect drug combination currently use St. Paul 's Hospital transplant centre .</brief_summary>
	<brief_title>A Pilot Study Comparing Use Low-target Versus Conventional Target Advagraf</brief_title>
	<detailed_description>Purpose This study design test whether use Thymoglobulin low dose tacrolimus early steroid withdrawal minimize kidney rejection development new onset diabetes transplant ( NODAT ) . Justification Experimental treatment low target tacrolimus thymoglobulin . Standard treatment standard target ( high dose ) tacrolimus basiliximab , instead thymoglobulin . The investigator hypothesize , combine approach early steroid withdrawal low dose tacrolimus low immunologic risk transplant recipient effective reduce incidence new onset diabetes mellitus , maintain low risk acute rejection . Objective The objective study compare early post-transplant outcome use low target versus standard target Advagraf de novo kidney allograft recipient low immunologic risk undergo early corticosteroid withdrawal . Research Method This pilot study . Primary secondary outcome follow : Primary Outcome Composite endpoint biopsy proven acute rejection NODAT 6 month post transplantation . Secondary Outcomes - Patient survival - Graft survival - Frequency , severity , treatment hypertension - Frequency , severity , treatment hyperlipidemia ( serum total cholesterol , ( high density lipoprotein ( HDL ) , low-density lipoprotein ( LDL ) , triglyceride ) - Weight gain - Infections ( cytomegalovirus ( CMV ) , opportunistic infection include urinary tract infection require treatment , pneumonia ) - Malignancy , include post-transplant lymphoproliferative disease ( PTLD ) - Leukopenia - Renal function measure serum creatinine estimate Glomerular Filtration Rate ( eGFR ) The primary endpoint evaluate time-to-event Kaplan Meier analysis Chi-squared analysis final 6 month data . Statistical Analysis Sample size power : In set early steroid withdrawal , Woodle et al . report acute rejection rate 14 % rATG 24 % interleukin-2 receptor antibody induction ( 10 ) . The incidence NODAT report 21 % Woodle , et al. , report 10 % low dose tacrolimus arm ELITE-Symphony trial . The investigator , therefore expect combine event rate 24 % Group A 45 % group B . With power 0.80 alpha error 0.05 , investigator determine investigator need 72 subject arm demonstrate 20 % difference composite primary outcome . For initial pilot study , investigator aim recruit total 30 subject After receive informed consent , subject randomized 1:1 basis one two treatment group . Subjects discontinue study prematurely replace .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>1 . Male female patient 18 year age receive decease , live unrelated living relate donor renal transplant 2 . No history preexist diabetes mellitus 3 . Not use diabetic medication ( insulin , hypoglycemic agent ) time transplantation 4 . Random plasma glucose level &lt; 11.1 time transplantation 5 . Peak PRA ( panel reactive antibody ) &lt; 10 % 6 . Females capable become pregnant must negative pregnancy test baseline require practice approve method birth control duration study period three month follow discontinuation study medication 7 . The patient give write informed consent participate study 1 . Patients primary nonfunction 2 . Peak PRA &gt; =10 % 3 . Multiple organ transplant 4 . HLA ( human leukocyte antigen ) identical living donor transplant recipient 5 . Cold ischemia time 24 hour 6 . Nonheart beat donor kidney recipient 7 . Pediatric donor kidney recipients 8 . Donor age &gt; =60 year 9 . Patients know positive hepatitis C serology , human immunodeficiency virus ( HIV ) Hepatitis B surface antigen positive . Laboratory result obtain within 6 month prior study entry acceptable . Recipients organs donor test positive Hepatitis B surface antigen Hepatitis C exclude . 10 . Presence severe allergy require acute ( within 4 week baseline ) chronic treatment , hypersensitivity drug similar use study 11 . Patients systemic infection 12 . Existence surgical medical condition , current transplant , opinion investigator , preclude enrollment trial 13 . Inability cooperate communicate investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Transplant</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Diabetes transplant</keyword>
	<keyword>Acute rejection prevention</keyword>
	<keyword>New onset diabetes transplant</keyword>
</DOC>